Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, GE Healthcare, Sanofi, and More


Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin

Patent Number: 8,835,401

Filed: May 29, 2013

Inventor: Martin Gleave, University of British Columbia

Title: Expression Cassettes for Seed-specific Expression in Plants

Patent Number: 8,835,622

Filed: Nov. 25, 2009

Lead Inventor: Franck Pinot, Bayer BioScience

Title: RNA Interference-mediated Inhibition of Catenin Beta 1 Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 8,835,623

Filed: Aug. 6, 2013

Lead Inventor: Duncan Brown, Sirna Therapeutics (Alnylam Pharmaceuticals)

Title: microRNA Scaffolds, Non-naturally Occurring microRNAs, and Methods for Optimizing Non-naturally Occurring microRNAs

Patent Number: 8,841,267

Filed: May 22, 2008

Lead Inventor: Melissa Kelley, Dharmacon (GE Healthcare)

Title: Polynucleotides for Use in Treating and Diagnosing Cancers

Patent Number: 8,841,269

Filed: Feb. 23, 2011

Inventor: Gary Xiao, Creighton University

Title: Use of Inhibitors of Zdhhc2 Activity for Modulation of Adipogenesis

Patent Number: 8,841,270

Filed: May 19, 2010

Lead Inventor: Diana Hall, Sanofi

Title: Double-stranded RNA-based Nanoparticles for Insect Gene Silencing

Patent Number: 8,841,272

Filed: May 31, 2012

Lead Inventor: Kun Yan Zhu, Kansas State University

Title: Precursor miRNA Loop-modulated Target Regulation

Patent Number: 8,841,437

Filed: May 28, 2010

Lead Inventor: Chang-Zheng Chen, Stanford University